Program

Please be aware that the conference schedule is subject to change without prior notice. We recommend checking this page and our official channels for updates.

Download Schedule

Schedule

Day 1 - Friday, March 28, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST AND REGISTRATION
9:00 AM	Introduction from conference organizers
9:05 AM	Opening remarks	Michael Teitell, MD, PhD University of California, Los Angeles
	PSMA Imaging Session 1
9:10 AM	History of PSMA	Martin Pomper, MD, PhD University of Texas, Southwestern
9:18 AM	Landscape of approved PSMA imaging agents: does it matter?	Amir Iravani, MD University of Washington
9:26 AM	Pictorial Atlas of PSMA PET	Matthias Benz, MD University of California, Los Angeles
9:34 AM	Impact of clinical guidelines on the utilization of PSMA PET	Emmanuel Antonarakis, MD University of Minnesota
9:42 AM	Panel discussion
	PSMA Imaging Session 2
9:50 AM	Who benefits from oligo-metastases directed therapy?	Julian Hong, MD, MS University of California, San Francisco
9:58 AM	PSMA-PET for overall survival outcomes risk stratification of prostate cancer	Wolfgang Fendler, MD University Hospital Essen, Germany
10:06 AM	WB PSMA quantitative parameters: Why are we not using WB PSMA PET parameters in the real world?	Irene Buvat, PhD Institut Curie, Orsay, France
10:14 AM	Panel discussion
10:20 AM	COFFEE BREAK
	PSMA Imaging Session 3
10:35 AM	The changing role of MRI in staging patients with prostate cancer	Steven Raman, MD University of California, Los Angeles
10:43 AM	Role of PSMA PET in surgical planning and post-operative management	Carissa Chu, MD University of California, San Francisco
10:51 AM	PSMA PET fusion guided biopsy	Wayne Brisbane, MD University of California, Los Angeles
10:59 AM	PRIMARY score and where it plays a role	Michael Hofman, FRACP, MBBS Peter MacCallum Cancer Centre, Melbourne, Australia
11:07 AM	Panel discussion
	PSMA Imaging Session 4
11:15 AM	Can we kill the bone scan?	Daniel Spratt, MD University Hospitals, Cleveland, OH
11:23 AM	How to crush a PSMA PET report: guidelines and scoring systems	Phillip Kuo, MD, PhD City of Hope, Los Angeles
11:31 AM	Incorporating PSMA PET into trial endpoints	Michael Morris, MD Memorial Sloan Kettering, New York
11:39 AM	Panel discussion + mini tumor board 1 [PET imaging]
12:15 PM	LUNCH BREAK
	LuPSMA Therapy Session 1
1:15 PM	Path to Clinical Use: Lesson from compassionate use in Germany	Wolfgang Fendler, MD University Hospital Essen, Germany
1:23 PM	Post-VISION: Real world experience in the US, how is PSMA RLT being used?	Matthew Rettig, MD University of California, Los Angeles
1:31 PM	Radiation Safety and Ecology: Comparison of practices across the US and the world	Catherine Meyer, PhD University of California, Los Angeles
1:39 PM	Panel discussion
	LuPSMA Therapy Session 2
1:45 PM	Pre-chemo trials: PSMAfore/SPLASH/ECLIPSE	Emmanuel Antonarakis, MD University of Minnesota
1:53 PM	Moving into the castration sensitive setting	Michael Morris, MD Memorial Sloan Kettering Cancer Center
2:01 PM	PSMA RLT for oligometastatic disease	Amar Kishan, MD University of California, Los Angeles
2:09 PM	Overview of enrolling Phase 2/3 trials	Jeremie Calais, MD, PhD University of California, Los Angeles
2:17 PM	Panel discussion
2:25 PM	COFFEE BREAK
	LuPSMA Therapy Session 3
2:40 PM	When should we use FDG PET?	Andrei Iagaru, MD Stanford University, California
2:48 PM	What’s the best way to evaluate response: SPECT vs PSMA PET?	Thomas Hope, MD University of California, San Francisco
2:56 PM	Moving beyond 6x6	Matthias Eiber, MD, PhD Technische Universität München, Germany
3:04 PM	Treatment Sequencing	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
3:12 PM	*Panel discussion + mini tumor board 2 [PSMA RLT]*	Andrei Iagaru, MD Matthias Eiber, MD, PhD Tanya Barauskas Dorff, MD
3:45 PM	Wrap up for the day
3:50 PM	Poster power pitches
4:05 PM	Poster session reception
4:50 PM	Poster awards + Closing

Day 2 - Saturday, March 29, 2025

Time	Title	Speaker
8:00 AM	BREAKFAST
	Dosimetry Session
9:00 AM	Are we underdosing?	Amir Iravani, MD University of Washington
9:08 AM	Lessons from radiation oncology: How can we improve PSMA RLT?	Daniel Spratt, MD University Hospitals, Cleveland, OH
9:16 AM	“Beyond the 23 Gray threshold”	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
9:24 AM	How to use quantitative dosimetry and act on it to adapt treatment	Carlos Uribe, PhD,MCCPM BC Cancer, University of British Columbia
9:32 AM	AI for Dosimetry	Irene Buvat, PhD Institut Curie, Orsay, France
9:40 AM	Panel discussion
	LuPSMA Therapy Session 4
9:50 AM	How are we getting paid for Theranostics and Dosimetry?	Denise Merlino, CPC, MBA, CNMT Merlino Healthcare Consulting, Florida
9:58 AM	PSMA RLT in a Medical Oncology private center	Luke Nordquist, MD Xcancer, Omaha, NE
10:06 AM	PSMA RLT in a Radiation Oncology private center	Dustin Boothe, MD Intermountain Health, Salt Lake City, UT
10:14 AM	Patient Experience	Mr. Kent Greer UCLA patient
10:22 AM	Panel discussion
10:30 AM	COFFEE BREAK
	Antibody and Other Ligands Session
10:45 AM	PSMA-I&T vs PSMA-617: Is there a difference?	Matthias Eiber, MD, PhD Technische Universität München, Germany
10:53 AM	Role of PSMA targeted antibodies	Scott Tagawa, MD, MS Weill Cornell Medicine, New York
11:01 AM	Next generation PSMA radioligands	Martin Pomper, MD, PhD University of Texas, Southwestern
11:09 AM	Panel discussion
	Alpha and Other Radionuclides Session
11:20 AM	How PSMA RLT kills the cells? Alpha vs beta radiobiology	Ana Ponce Kiess, MD, PhD Johns Hopkins University, Baltimore, MD
11:28 AM	Ac225 PSMA experience	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:36 AM	Management of dry mouth	Sue Yom, MD, PhD University of California, San Francisco
11:44 AM	Pb212 PSMA vs Ac225 PSMA: From biology to supply	Alfred Morgenstern, PhD Joint Research Centre, Karlsruhe, Germany
11:52 AM	Tb161 Experience at Peter MacCallum Cancer Center	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
12:00 PM	Panel discussion
12:10 PM	LUNCH BREAK
	Targeting PSMA with CAR-T, ADC, BisAb: Comparison with RLT
1:10 PM	CAR-T and Bispecific Antibodies targeting PSMA	Tanya Barauskas Dorff, MD City of Hope, Los Angeles
1:18 PM	Role of ADCs in prostate cancer	John K. Lee, MD, PhD University of California, Los Angeles
1:26 PM	Value of animal models in evaluating PSMA-targeted RPT and non-RPT therapies	Deborah Charych, PhD Utter Therapeutics
1:34 PM	Panel discussion	Tanya Barauskas Dorff, MD John K. Lee, MD, PhD Matthew Rettig, MD Deborah Charych, PhD Scott Tagawa, MD, MS
	Keynote Lecture
1:50 PM	Improving outcomes with combination therapy	Michael Hofman, FRACP,MBBS Peter MacCallum Cancer Centre, Australia
2:10 PM	Panel discussion	Emmanuel Antonarakis, MD Tanya Barauskas Dorff, MD Michael Hofman, FRACP,MBBS Michael Morris, MD
	New Developments in GU Radioligand Therapy
2:25 PM	GRPR and other peptides for targeting prostate cancer	Andrei Iagaru, MD Stanford University, California
2:33 PM	DLL3, CD46, STEAP1 and others	Robert Flavell, MD, PhD University of California, San Francisco
2:41 PM	HK2 and HK3 experience	David Ulmert, MD University of California, Los Angeles
2:49 PM	TROP2 and other Promising Targets for Imaging and Therapy	Tanya Stoyanova, PhD University of California, Los Angeles
2:57 PM	CA-IX in renal cell cancer	Brian Shuch, MD University of California, Los Angeles
3:05 PM	Opportunity for RLT in bladder cancer	Vadim Koshkin, MD University of California, San Francisco
3:13 PM	Panel discussion
3:30 PM	Closing comments